Royalty Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	770.95	858.98	1,135	42.83	619.73
Depreciation & Amortization	3.85	-	-	5.67	23
Other Amortization	28.64	19.56	20.5	21.36	20.16
Asset Writedown & Restructuring Costs	-	-	-	615.83	-
Loss (Gain) From Sale of Investments	-24.01	-194.46	-317.98	40.26	30.21
Loss (Gain) on Equity Investments	-15.69	-16.22	-10.06	48.12	53.87
Stock-Based Compensation	289.89	2.34	2.36	2.17	2.44
Provision & Write-off of Bad Debts	-295.84	732.46	560.66	904.24	452.84
Other Operating Activities	-1,606	-1,670	-1,609	-2,076	-1,484
Change in Accounts Receivable	3,355	2,983	3,201	2,507	2,296
Change in Accounts Payable	-13.93	-2.29	6.24	2.29	-4.59
Change in Other Net Operating Assets	-3.22	55.67	-0.85	30.38	8.4
Operating Cash Flow	2,490	2,769	2,988	2,144	2,018
Operating Cash Flow Growth	-10.08%	-7.32%	39.36%	6.27%	-0.84%
Cash Acquisitions	-74.42	-	-	-	-
Sale (Purchase) of Intangibles	-1,698	-2,506	-2,116	-1,742	-2,192
Investment in Securities	438.22	-99.45	57.17	712.22	339.82
Other Investing Activities	-280.26	-72.96	-14.44	-	-18.6
Investing Cash Flow	-1,614	-2,678	-2,073	-1,029	-1,870
Short-Term Debt Issued	1,275	-	350	-	-
Long-Term Debt Issued	1,954	1,471	-	-	1,273
Total Debt Issued	3,229	1,471	350	-	1,273
Short-Term Debt Repaid	-1,275	-	-350	-	-
Long-Term Debt Repaid	-1,000	-	-1,000	-	-
Total Debt Repaid	-2,275	-	-1,350	-	-
Net Debt Issued (Repaid)	954.48	1,471	-1,000	-	1,273
Repurchase of Common Stock	-1,227	-229.65	-304.76	-	-
Common Dividends Paid	-378.25	-376.47	-358.33	-333.32	-285.18
Other Financing Activities	-534.81	-503.97	-485.67	-611.53	-602.24
Financing Cash Flow	-1,186	361.15	-2,149	-944.86	385.11
Net Cash Flow	-310.33	452.02	-1,234	169.7	532.37
Cash Interest Paid	276.29	159.57	169.17	170.14	130.43
Levered Free Cash Flow	-670.41	-1,758	-1,244	-1,384	-1,547
Unlevered Free Cash Flow	-500.56	-1,636	-1,148	-1,288	-1,463
Change in Working Capital	3,338	3,037	3,207	2,540	2,300

Updated Feb 11, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q